Search

Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever. Their application in the form of conjugates with protein carriers eliminate the gap in protection against these infections in children under one year. Extremely promising turned out offered us a new generation of vaccines, which have synthetic peptides conjugated to a meningococcal polysaccharide. Thus, new approaches to the solution of the problem of meningococcal disease vaccination serogroup B were open. In recent years, Russian researchers first suggested to use IgA1 protease (one of the major virulence factors of microbes and almost identical for mentioned below infections) for prevention of such diseases as meningococcal of all serogroups, pneumococcus and hemophilia infections. Patented processes for producing of the vaccine define domestic priority of its production and use.

IgA1-protease allocated from the culture N. meningitidis serogroup A. As original materials were used three different intermediate products of vaccine production: cultural fluid, cetavlon supernatant and cetavlon precipitate. IgA1-protease was used to evaluate their protectivity and immunogenity. It was shown, that isolated IgA1 protease from the meningococcus serogroup A is able to protect mice, infected by meningococcus serogroup B.

The immunogenic and protective activities of recombinant IgA1 serine protease obtained on the base of the genome DNA of N. meningitidis serogroup B strain H44/76 were studied. A several recombinant proteins of different molecular weights that are based on the full-length primary structure of the enzyme, taking into account the distribution of B- and T-epitopes, also were studied. In experiments on laboratory animals it was shown that a number of tested preparations demonstrate the immunogenic and protective activity to protect mice from lethal challenge with virulent strains of meningococcus serogroups A, B and C, thereby exhibiting polyvaccine properties. The protective role of antibodies against the IgA1 protease was shown when mice were infected by meningococccus serogroup B. The increase in antibodies to the meningococcal IgA1 protease into the blood of rabbits infected with different serotypes of pneumococci has been detected, indicating potential ability of the meningococcal IgA1 protease to generate protection against microbes the virulence of which is caused by IgA1protease.